FOXP3 in Melanoma with Regression: Between Tumoral Expression and Regulatory T Cell Upregulation. (23rd October 2020)

• Record Type: Journal Article
• Authors: Cioplea, Mirela; Nichita, Luciana; Georgescu, Daniela; Sticlaru, Liana; Cioroianu, Alexandra; Nedelcu, Roxana; Turcu, Gabriela; Rauta, Alin; Mogodici, Cristian; Zurac, Sabina; Popp, Cristiana
• Other Names: Popescu Iulia Dana Academic Editor.
• Is Part Of: Journal of immunology research. Volume 2020(2020)
• Publication Date: 2020-10-23
• Subjects: Immunology -- Periodicals; Immunology -- Research -- Periodicals; 616.07905
• DOI: 10.1155/2020/5416843
• Languages: English
• ISSNs: 2314-8861

Abstract

Abstract : Cutaneous melanoma is a significant immunogenic tumoral model, the most frequently described immune phenomenon being tumor regression, as a result of the interaction of tumoral antigens and stromal microenvironment. We present a retrospective cohort study including 52 cases of melanoma with regression. There were evaluated correlations of the most important prognostic factors (Breslow depth and mitotic index) with FOXP3 expression in tumor cells and with the presence of regulatory T cells and dendritic cells in the tumoral stroma. FOXP3 expression in tumor cells seems an independent factor of poor prognosis in melanoma, while regression areas are characterized by a high number of dendritic cells and a low number of regulatory T cells. FOXP3 is probably a useful therapeutical target in melanoma, since inhibition of FOXP3-positive tumor clones and of regulatory T cells could eliminate the ability of tumor cells to escape the immune defense of the host.